The current study report the effect of Src inhibition in both the early stage and in in the more progressed stage of bone cancer pain and finds a delay in onset of pain-related behaviours post inoculation of 5·103 MRMT-1 cells, thus supporting the finding by Felice et al. The gene discussed is SRC; the disease is bone cancer.